Today, we’re joined by two leaders at nChroma Bio, a company working to redefine the future of genetic medicine through epigenetic engineering and next-generation targeted delivery technologies.

Melissa Bonner, Chief Scientific Officer, and Dr. Jenny Marlowe, Chief Development Officer, are helping lead the development of therapies designed not just to edit genes, but to control how genes are turned on and off — without permanently changing the underlying DNA sequence.

nChroma is combining programmable epigenetic editors with advanced delivery systems like lipid nanoparticles and engineered virus-like particles to create highly targeted therapies for diseases affecting the liver, cardiovascular system, blood, and central nervous system. Their lead program, CRMA-1001, is being developed as a potential functional cure for chronic hepatitis B and hepatitis D.

What makes this especially exciting is that nChroma’s approach aims to regulate gene expression in a durable and potentially safer way than traditional gene editing approaches that cut DNA.